A new promising therapy for advanced, or metastatic, esophageal cancer was recently approved by the Food and Drug Administration (FDA). This new drug belongs to a class of immunotherapy agents and ...

"Adding sintilimab -- or this kind of immunotherapy regimen -- to neoadjuvant chemoradiotherapy may improve pathological outcomes without increasing surgical risks," said Leng at the American ...

The results of these trials could cement ICI-based immunotherapy as the new standard systemic treatment option for esophageal cancer.

Zaidi said the five-year survival rate for patients with advanced esophageal cancer is typically less than 20%. With the experimental doublet immunotherapy drug combination, data show a promising ...

Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is one of the most prevalent digestive ...

Does the time of day of immunotherapy infusions affect patients ... renal cell carcinoma, and esophageal cancer, as well as both locally advanced and metastatic non–small cell lung cancer ...

Medscape Medical News, January 28, 2025 GICS 2025 Immunotherapy + CRT Boosts Response in Esophageal Cancer The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological ...

Researchers at Case Western Reserve University have discovered molecules that present the potential to drive the development of gastric cancer-among the world's deadliest forms of the disease.

Driven by obesity and acid reflux, esophageal cancer has become the fastest rising cancer in Caucasian men in the United States. The thoracic oncologists and gastroenterologists at the Baylor St. Luke ...